BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-21.24%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.48B
AUM Growth
+$9.48B
(-21%)
Cap. Flow
+$482M
Cap. Flow
% of AUM
5.09%
Top 10 Holdings %
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5
Top Buys
| 1 |
Incyte
INCY
|
$292M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$208M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$104M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$57M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$56.1M |
Top Sells
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
$313M |
| 2 |
Gilead Sciences
GILD
|
$25.3M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$15.2M |
| 4 |
WINT
Windtree Therapeutics Inc
WINT
|
$5.54M |
| 5 |
Iovance Biotherapeutics
IOVA
|
$3.82M |
Sector Composition
| 1 | Healthcare | 77.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Insmed
INSM
$28.8B
| $19M | 0.2% | 1,500,000 +500,000 | +50% | +$6.34M |
|
|
PGNX
27
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $19M | 0.2% | 4,350,808 | – | – |
|
28
Halozyme
HALO
$8.56B
| $18.3M | 0.19% | 1,931,057 | – | – |
|
29
TG Therapeutics
TGTX
$4.65B
| $17.1M | 0.18% | 2,003,991 | – | – |
|
|
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $16.9M | 0.18% | 609,166 | – | – |
|
|
XNPT
31
DELISTED
XENOPORT, INC.
XNPT
| $15.7M | 0.17% | 3,475,672 | – | – |
|
|
MDVN
32
DELISTED
MEDIVATION, INC.
MDVN
| $15.2M | 0.16% | 329,876 -329,876 | -50% | -$15.2M |
|
|
BLUE
33
DELISTED
bluebird bio
BLUE
| $15M | 0.16% | 352,943 +211,838 | +150% | +$9M |
|
|
FOMX
34
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $14.6M | 0.15% | 2,241,702 +194,735 | +10% | +$1.27M |
|
|
ACGN
35
DELISTED
Aceragen, Inc. Common Stock
ACGN
| $13.8M | 0.15% | 6,990,189 +7,082 | +0.1% | +$14K |
|
|
ARRY
36
DELISTED
Array Biopharma Inc
ARRY
| $12.7M | 0.13% | 4,310,666 | – | – |
|
37
Galapagos
GLPG
$2.07B
| $12.7M | 0.13% | 303,394 -65,882 | -18% | -$2.76M |
|
38
Agios Pharmaceuticals
AGIO
$2.19B
| $12.5M | 0.13% | 307,915 +207,915 | +208% | +$8.44M |
|
39
Novavax
NVAX
$1.21B
| $12.3M | 0.13% | 2,379,254 +183,567 | +8% | +$947K |
|
40
Xencor
XNCR
$580M
| $11.7M | 0.12% | 872,072 | – | – |
|
|
DSCI
41
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $11.6M | 0.12% | 3,752,390 | – | – |
|
42
Omeros
OMER
$283M
| $11.5M | 0.12% | 749,250 +413,024 | +123% | +$6.34M |
|
43
Exelixis
EXEL
$10.1B
| $10.3M | 0.11% | +2,580,000 | New | +$10.3M |
|
|
DMTX
44
DELISTED
Dimension Therapeutics, Inc
DMTX
| $9.8M | 0.1% | 1,251,881 +17,400 | +1% | +$136K |
|
|
GBT
45
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.52M | 0.1% | 600,000 +200,000 | +50% | +$3.17M |
|
46
Ascendis Pharma
ASND
$11.8B
| $9.38M | 0.1% | 505,521 | – | – |
|
|
ZGNX
47
DELISTED
Zogenix, Inc.
ZGNX
| $9.24M | 0.1% | 1,000,000 | – | – |
|
48
Arcturus Therapeutics
ARCT
$462M
| $8.86M | 0.09% | 2,336,359 | – | – |
|
49
Alkermes
ALKS
$4.78B
| $8.56M | 0.09% | 250,251 | – | – |
|
|
ATYR
50
aTyr Pharma
ATYR
$527M
| $8.42M | 0.09% | 2,137,606 -197,519 | -8% | -$778K |
|